A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
Phase 1
- Conditions
- HIV Infections
- Registration Number
- NCT00048217
- Lead Sponsor
- Trimeris
- Brief Summary
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Completion T1249-102;
- Currently failing a T-20 containing regimen
Exclusion Criteria
- Non-completion of T1249-102.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Trimeris
🇺🇸Durham, North Carolina, United States
Trimeris🇺🇸Durham, North Carolina, United States